Carplatin 450 IV Infusion 45ml

✔️ Dosage & Administration: Carplatin 450Carplatin 450

• Avoid using needles or IV sets with aluminum parts, as aluminum reacts with Carboplatin, leading to reduced potency or precipitation.
• Intravenous (IV) only, after proper dilution.
• Adult Dosage (normal kidney function):

• 400 mg/m² as a single IV dose, administered over 15–60 minutes.
• Therapy should be repeated every 4 weeks, depending on hematologic recovery: neutrophils ≥ 2000/mm³ and platelets ≥ 100,000/mm³.

• For patients with risk factors (e.g., prior myelosuppressive therapy, poor performance status, or age ≥ 65), reduce the initial dose by 20-25% (to 300-320 mg/m²).
• Weekly blood counts are recommended during the first course of therapy to adjust dosage for subsequent courses.sage & Administration
• Avoid using needles or IV sets with aluminum parts, as aluminum reacts with Carboplatin, leading to reduced potency or precipitation.
• Intravenous (IV) only, after proper dilution.

Adult Dosage (normal kidney function):

• 400 mg/m² as a single IV dose, administered over 15–60 minutes.
• Therapy should be repeated every 4 weeks, depending on hematologic recovery: neutrophils ≥ 2000/mm³ and platelets ≥ 100,000/mm³.

• For patients with risk factors (e.g., prior myelosuppressive therapy, poor performance status, or age ≥ 65), reduce the initial dose by 20-25% (to 300-320 mg/m²).
• Weekly blood counts are recommended during the first course of therapy to adjust dosage for subsequent courses.

✔️ Interaction

• Should not be mixed with other drugs during administration.
• Renal toxicity may increase when combined with neurotoxic or nephrotoxic drugs.

✔️ Carboplatin is contraindicated in:

1. Severe renal impairment (unless benefits outweigh risks).
2. Severe myelosuppression.
3. History of severe allergic reactions to Carboplatin, other platinum compounds, or mannitol.
4. Patients with bleeding tumors.

✔️ Side Effects of Carplatin 450

Hematologic Toxicity:

• Bone marrow suppression (dose-limiting): Thrombocytopenia, neutropenia, leucopenia, and anemia.
• Recovery time: 35-42 days after nadir (lowest blood count).
• Risk factors: Kidney impairment, older age (>65), and prior chemotherapy.
• Possible complications: Infection (4%) and hemorrhage (5%).

Nephrotoxicity:

• Abnormal renal function (e.g., elevated creatinine or BUN levels).
• Creatinine clearance is the most sensitive indicator.
• Electrolyte imbalances: Decreased sodium, potassium, calcium, and magnesium.

Gastrointestinal Toxicity:

• Nausea (15%), vomiting (65%), diarrhea (6%), constipation (6%), and anorexia.
• Usually resolves within 24 hours; antiemetics can help.

Allergic Reactions:

• Rare (<2%): Rash, fever, pruritus, urticaria, bronchospasm, or hypotension.

Hepatic Toxicity:

• Mild and reversible abnormalities in liver enzymes (e.g., SGOT, alkaline phosphatase).

Neurotoxicity:

• Peripheral neuropathies (4%): Paresthesia, decreased reflexes.
• Central nervous system symptoms (5%): This may be linked to antiemetics.

✔️ Pregnancy & Lactation

• Pregnancy: Category D – Evidence of fetal risk exists. Use only if the potential benefit justifies the risk.
• Lactation: Carboplatin may be excreted in breast milk; avoid use during breastfeeding.

✔️ Precautions & Warnings

• Administer under the supervision of a qualified physician experienced in chemotherapy.
• Perform regular monitoring of:
  • Blood counts (weekly during initial therapy).
  • Renal and hepatic function.
  • Neurological function.
• Avoid repeating treatment more frequently than once per month.
• Consider dose adjustments for renal impairment or combination therapy with other myelosuppressive drugs.
• Supportive measures (e.g., transfusions) may be required for severe myelosuppression.
• Use antiemetics to manage nausea and vomiting.

✔️ Storage Conditions

• Store below 25°C in a dry place.
• Do not refrigerate.
• Keep out of reach of children.